Urinary Tract Infection Therapeutics: By Indication (Complicated UTI, Uncomplicated UTI and Other), By Drug Type (Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other) And Region - Global Analysis of Market Size, Share & Trends for 2019-2020 And Forecasts to 2031
Global Urinary Tract Infection Therapeutics to surpass USD 10.6 billion by 2031 from USD 7.4 billion in 2021 at a CAGR of 3.7% in the coming years, i.e., 2021-31.
UTI (Urinary tract infection) is among the most common health problems. Because women encounter health issues such as menstruation, pregnancy, and some birth control side effects, UTI is much more common among women than in males. A person who has diabetes and then develops urological health problems is inextricably linked. Diabetes exacerbates health problems and increases the chance of UTIs, as well as bladder problems. Diabetes can also cause and result in the worsening of complications such as urologic difficulties and diseases. This is due to the fact that they are known to affect an individual's blood flow, neuron functions, and sensory processes.
Global Urinary Tract Infection Therapeutics market is expected to project a notable CAGR of 3.7% in 2031.
Global Urinary Tract Infection Therapeutics to surpass USD 10.6 billion by 2031 from USD 7.4 billion in 2021 at a CAGR of 3.7% in the coming years, i.e., 2021-31. As the prevalence of diabetes & kidney stones rises, so does the majority of cases of urinary tract infection, which drives up medicine demand and hence propels the worldwide urinary infection therapeutic market.
Uncomplicated UTI segment to grow with the highest CAGR during 2021-31
Based on indication global Urinary Tract Infection Therapeutics is categorized into Complicated UTI, Uncomplicated UTI and Other. The uncomplicated UTI market accounts the highest market growth. The most frequent type of UTI now impacting the worldwide population is uncomplicated UTIs. Antibiotics are usually prescribed to treat UTIs. Because of the rising number of hospital-acquired infections, particularly catheter-associated UTIs, the uncomplicated UTI category is expected to lead the global urinary tract infection therapies in the coming year.
Quinolones segment to grow with the highest CAGR during 2021-31
Global Urinary Tract Infection Therapeutics is segmented in the basis of Drug type into Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitro furans and Other. The quinolones category retained the greatest share of the market, which also consist of penicillin and combination sector is expected to grow at the fastest rate over the forecast period. As they are available in hospital and retail pharmacies. The fact that quinolones are routinely recommended by physicians is largely responsible for the market's future growth. Fluoroquinolones, ofloxacin, & enoxacins are among the most commonly prescribed antibiotics.
Increasing in prevalence of UTIs
Due to the anatomy, women are more likely than males to get a urinary tract infection. Several women have had urinary tract infections multiple times in their lives. Urinary tract infections are caused by a variety of circumstances, including hormonal changes, poor personal cleanliness, catheter use, and others. The urinary tract infection therapeutics industry is predicted to grow significantly in the next years as the occurrence of urinary tract infection rises.
Rising demand for Antibiotic consumption
The only treatment choices for a urinary tract infection are antibiotics. A wide spectrum of antibiotics is provided depending on the seriousness of the infection. Fluoroquinolones, trimethoprim/sulfamethoxazole, and aminoglycosides, for example, are used as first-line treatments for uncomplicated urinary tract infections. When. Similarly, in cases of less severe infections, fluoroquinolones like ciprofloxacin or ofloxacin are indicated for difficult urinary tract infection treatment. Aside from these, the availability of low-cost antibiotics from generic firms and the regulations governing patent rights for branded pharmaceuticals are two factors that are predicted to drive the expansion of the urinary tract infection(UTI) therapeutics industry.
Complicated legal obligations
Presently, the process of developing antibacterial medications and conducting clinical trials is a lengthy and complicated one. Furthermore, the lack of a scientific and ethical approach during these measures is likely to limit the market's ability to grow as expected during the evaluation phase.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Global Urinary Tract Infection Therapeutics market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific and the Middle East and Africa. The North American region includes countries that results in the growth of the global urine tract infection therapeutic market. The North American market is anticipating a significant increase in investment in research & development of treatment goods and diagnostics that will aid in the global expansion of the urinary tract infection (UTI) industry. Because of the expanding prevalence of Urinary infections and renal issues among the populations of this region, the United States has a growing global market share.
The unexpected rise of coronavirus-infected patients hampered access to other primary care treatments, resulting in a large decline in non-COVID-19-related diagnoses such urinary tract infection. In 2020, the rate of UTI diagnostic decreased somewhat, possibly slowing the industry's expansion in recent months. A considerable decline in urinary infection (UTI) diagnosis associated to the COVID-19 pandemic is cause for concern. As a result, fewer people sought primary care services, and fewer diagnoses, such as UTIs.
Market size value in 2021
USD 7.4 billion
Revenue forecast in 2031
USD 10.6 billion
CAGR of 3.7% from 2021 to 2031
Base year for estimation
Revenue in USD million and CAGR from 2021 to 2031
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Drug Type, Indication and Region
North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Key companies profiled
Bayer AG, Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Lupin Ltd., Merck & Co., Inc, Almirall, S.A and Other Prominent Players.
Urinary Tract Infection Therapeutics market size was estimated at USD 7.4 billion in 2021 and is expected to reach USD 10.6 billion in 2031.
A person who has diabetes and then develops urological health problems is inextricably linked. Diabetes exacerbates health problems and increases the chance of UTIs, as well as bladder problems.
Quinolones and Uncomplicated UTIs are segments accounted for the largest Urinary Tract Infection Therapeutics chain market share.
Key players: Bayer AG, Pfizer, Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Lupin Ltd., Merck & Co., Inc, Almirall, S.A are the key players in the Urinary Tract Infection Therapeutics market.
Increasing in prevalence of UTIs and Increasing demand for Antibiotic consumption these are factors driving the growth of this market.
Select License Type
US : +1 (716) 218-3733
UK : +44 (208) 1235555
Select License Type
FATPOS CLIENT Appriciation DURING THE PROJECT